How should Broncofil N (acebrophylline + N‑acetylcysteine) be administered, what is the recommended dosage, its indications, contraindications, and common adverse effects?

Broncofil N (Acebrophylline + N-Acetylcysteine)

I cannot provide specific dosing, administration, or safety information for Broncofil N as this proprietary combination product is not included in the provided evidence base, which contains no FDA labeling or manufacturer guidelines for this specific formulation.

What the Evidence Shows About the Individual Components

N-Acetylcysteine in Chronic Respiratory Disease

N-acetylcysteine has demonstrated efficacy in reducing exacerbations in chronic bronchitis and COPD, particularly at higher doses. 1

Dosing Evidence for N-Acetylcysteine:

• Standard dose: 600 mg/day has shown benefit in chronic bronchitis patients without airway obstruction 2
• High dose: ≥1200 mg/day (typically 600 mg twice daily) is more effective in COPD patients with documented airway obstruction 2
• The ACCP/CTS guidelines suggest N-acetylcysteine for patients with moderate to severe COPD and history of ≥2 exacerbations in the previous 2 years 1
• The ERS/ATS guidelines recommend oral mucolytic agents (including N-acetylcysteine 600 mg twice daily) for patients with moderate or severe airflow obstruction and exacerbations despite optimal inhaled therapy 1

Safety Profile:

• N-acetylcysteine is well-tolerated at doses up to 3000 mg/day 3
• Gastrointestinal symptoms are the most common adverse effects but occur at similar rates to placebo 4
• Withdrawal rates due to adverse effects are comparable to placebo (6.5% vs 7.1%) 4
• No dose-dependent increase in adverse reactions 2

Acebrophylline (Theophylline Derivative)

The evidence base does not contain specific information about acebrophylline. However, regarding theophylline in general:

• In stable COPD: Theophylline may reduce chronic cough but requires careful monitoring for complications 1
• In acute exacerbations: Theophylline should NOT be used (Grade D recommendation) 1
• The ACCP/CTS guidelines suggest oral slow-release theophylline twice daily for stable COPD patients to prevent exacerbations, but emphasize the narrow therapeutic window and need for vigilance regarding drug interactions 1

Recent Combination Study

One recent study evaluated the specific combination of N-acetylcysteine and acebrophylline (branded as "Abiways") in 97 patients with moderate to severe COPD and asthma 5:

• FEV1 improvement: Significant increase from 1.287L to 1.484L (p<0.001) 5
• Quality of life: COPD patients showed significant CAT score improvement (17.2 to 10.6, p=0.0001) 5
• Safety: No severe adverse events reported 5
• Duration: 90-day treatment period as add-on therapy 5

Critical Limitations

I cannot recommend specific dosing, contraindications, or administration protocols for Broncofil N without access to:

• FDA-approved labeling or equivalent regulatory documentation
• Manufacturer's prescribing information
• Country-specific regulatory approval data
• Specific formulation details (immediate vs. sustained release, exact dosage strengths)

Clinical Context from Guidelines

For patients with chronic bronchitis or COPD, the evidence-based approach prioritizes 1:

1. First-line: Short-acting β-agonists and/or ipratropium bromide (Grade A)
2. Moderate-severe disease: Long-acting bronchodilators ± inhaled corticosteroids
3. Adjunctive mucolytic therapy: Consider for patients with ≥2 exacerbations/year despite optimal inhaled therapy 1

Consult the product's official prescribing information, local regulatory guidelines, or the manufacturer directly for specific dosing and safety information for Broncofil N.